Bisphosphonate

This page covers all Bisphosphonate drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting Farnesyl pyrophosphate synthase (FPPS); hydroxyapatite binding, Farnesyl pyrophosphate synthase; hydroxyapatite in bone, Farnesyl pyrophosphate synthase (FPPS); hydroxyapatite.

Targets

Farnesyl pyrophosphate synthase (FPPS); hydroxyapatite binding · Farnesyl pyrophosphate synthase; hydroxyapatite in bone · Farnesyl pyrophosphate synthase (FPPS); hydroxyapatite · Farnesyl pyrophosphate synthase · Farnesyl pyrophosphate synthase (indirect); hydroxyapatite binding · Farnesyl pyrophosphate synthase (indirect); hydroxyapatite in bone (binding site) · Hydroxyapatite (bone mineral); osteoclast farnesyl pyrophosphate synthase · 72 kDa type IV collagenase · Farnesyl pyrophosphate synthase (mevalonate pathway); hydroxyapatite binding · Hydroxyapatite

Marketed (20)

• Alendronate (Fosamax) · Medical University of South Carolina · Bone metabolism / Rheumatology
  Alendronate inhibits osteoclast-mediated bone resorption by binding to hydroxyapatite on bone surfaces and blocking the enzyme farnesyl pyrophosphate synthase in the mevalonate pathway.
• Ibandronate IV · National Taiwan University Hospital · Bone metabolism / Osteoporosis
  Ibandronate is a bisphosphonate that inhibits osteoclast-mediated bone resorption by binding to hydroxyapatite in bone and blocking farnesyl pyrophosphate synthase in the mevalonate pathway.
• Ibandronate (SB743830HD) · GlaxoSmithKline · Bone metabolism / Osteoporosis
  Ibandronate is a bisphosphonate that inhibits osteoclast-mediated bone resorption by binding to hydroxyapatite in bone and blocking farnesyl pyrophosphate synthase in the mevalonate pathway.
• Ibandronate (Bondronat) · Chinese Society of Lung Cancer · Oncology; Bone metabolism
  Ibandronate is a bisphosphonate that inhibits osteoclast-mediated bone resorption by binding to hydroxyapatite in bone and blocking farnesyl pyrophosphate synthase in the mevalonate pathway.
• Alendronate (ALN) · Chinese University of Hong Kong · Bone metabolism / Rheumatology
  Alendronate inhibits osteoclast-mediated bone resorption by binding to hydroxyapatite on the bone surface and blocking farnesyl pyrophosphate synthase in the mevalonate pathway.
• Effervescent and buffered alendronate · Aarhus University Hospital · Bone metabolism / Osteoporosis
  Alendronate is a bisphosphonate that inhibits osteoclast-mediated bone resorption by binding to hydroxyapatite in bone and blocking farnesyl pyrophosphate synthase in the mevalonate pathway.
• Generic Zoledronic Acid · Cttq · Oncology, Bone Metabolism
  Zoledronic acid inhibits osteoclast-mediated bone resorption by blocking farnesyl pyrophosphate synthase in the mevalonate pathway.
• Risedronate Sodium (Actonel) · Sanofi · Bone metabolism / Osteoporosis
  Risedronate is a bisphosphonate that inhibits osteoclast-mediated bone resorption by binding to hydroxyapatite on the bone surface and blocking farnesyl pyrophosphate synthase in the mevalonate pathway.
• OST · Pharmbio Korea Co., Ltd. · Osteoporosis
  OST is an osteoclast inhibitor.
• Didronel · Procter And Gamble · Bone
• ibandronate [Bonviva/Boniva] · Hoffmann-La Roche · Bone metabolism / Osteoporosis
  Ibandronate is a bisphosphonate that inhibits osteoclast-mediated bone resorption by binding to hydroxyapatite in bone and blocking the mevalonate pathway in osteoclasts.
• Placebo to zoledronic acid · Amgen · Oncology; Bone metabolism disorders
  Zoledronic acid is a bisphosphonate that inhibits osteoclast-mediated bone resorption by binding to hydroxyapatite in bone and blocking farnesyl pyrophosphate synthase in the mevalonate pathway.
• Risedronate (HMR4003) · Sanofi · Bone metabolism / Rheumatology
  Risedronate inhibits bone resorption by binding to hydroxyapatite on bone surfaces and inhibiting osteoclast activity.
• Zolendronic Acid · Wales Cancer Trials Unit · Oncology, Bone Metabolism
  Zoledronic acid inhibits osteoclast-mediated bone resorption by blocking farnesyl pyrophosphate synthase in the mevalonate pathway.
• Aredia · Oncology
• Skelid · Bone
• Alendronate and Zoledronate · National Taiwan University Hospital · Bone metabolism / Osteoporosis
  Bisphosphonates that inhibit osteoclast-mediated bone resorption by binding to hydroxyapatite on bone surfaces and reducing osteoclast activity.
• ZA · Merck Sharp & Dohme LLC · Oncology, Bone Metabolism
  ZA is a bisphosphonate that inhibits bone resorption by suppressing osteoclast activity and promoting osteoclast apoptosis.
• ZOL · Eisai Inc. · Oncology, Bone Metabolism
  ZOL (zoledronic acid) is a bisphosphonate that inhibits osteoclast-mediated bone resorption by blocking farnesyl pyrophosphate synthase in the mevalonate pathway.
• Boniva · Hoffmann La Roche · Bone

Phase 3 pipeline (10)

• Placebo to Alendronate · Amgen · Osteoporosis
  Alendronate works by inhibiting osteoclast-mediated bone resorption.
• Actonel (Risedronate) · M.D. Anderson Cancer Center · Bone metabolism / Rheumatology
  Risedronate inhibits bone resorption by binding to hydroxyapatite on bone surfaces and inhibiting osteoclast activity.
• AXS-02 (oral zoledronate) · Axsome Therapeutics, Inc. · Bone metabolism / Oncology
  AXS-02 is an oral formulation of zoledronate, a bisphosphonate that inhibits osteoclast-mediated bone resorption by blocking farnesyl pyrophosphate synthase in the mevalonate pathway.
• Dimephosphon® · Tatchempharmpreparaty, JSC · Bone metabolism / Rheumatology
  Dimephosphon is a bisphosphonate that inhibits bone resorption by suppressing osteoclast activity and promoting osteoclast apoptosis.
• Minodronic acid hydrate · Ono Pharmaceutical Co. Ltd · Bone metabolism / Osteoporosis
  Minodronic acid is a bisphosphonate that inhibits osteoclast-mediated bone resorption by blocking farnesyl pyrophosphate synthase in the mevalonate pathway.
• risedronate combine · Hanlim Pharm. Co., Ltd. · Osteoporosis
  Risedronate combines with other medications to inhibit bone resorption by acting on osteoclasts.
• Alendronate sodium hydrate · Daiichi Sankyo Co., Ltd. · Bone metabolism / Osteoporosis
  Alendronate sodium inhibits osteoclast-mediated bone resorption by binding to hydroxyapatite on the bone surface and blocking farnesyl pyrophosphate synthase in the mevalonate pathway.
• Zoledronic acid i.v. 2 years · Ludwig-Maximilians - University of Munich · Oncology, Bone Diseases
  Zoledronic acid i.v. inhibits bone resorption by acting as a bisphosphonate.
• Soludronate® · Xeolas Pharmaceuticals Limited · Bone metabolism / Osteoporosis
  Soludronate is a bisphosphonate that inhibits osteoclast-mediated bone resorption by binding to hydroxyapatite in bone and disrupting the mevalonate pathway in osteoclasts.
• Zoledronic acid i.v. 5 years · Ludwig-Maximilians - University of Munich · Oncology, Bone Diseases
  Zoledronic acid i.v. inhibits bone resorption by acting as a bisphosphonate.

Phase 2 pipeline (1)

• Intravenous Infusion of Aclasta® · AUVA Traumazentrum Vienna Site UKH Meidling · Oncology
  Bisphosphonate that inhibits osteoclast-mediated bone resorption